Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients

7 Apr 2022

Abstract excerpt

(AveXis, now Novartis) place vectors derived from adeno-associated viruses (AAV) among the best options for gene transfer in multiple tissues. Despite these successes, limitations remain to the application of this therapeutic modality in a wider population. AAV was originally identified as a promising virus to derive gene therapy vectors because, despite infecting humans, it was not associated with any evident...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Viral gastroenteritis research and epidemiology
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35464422
DOI: 10.3389/fimmu.2022.857276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive PatientsPMID 35464422Read ↗

Humoral immune responses to AAV gene therapy in the ocular compartmentSemantic proximity Read ↗

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.Semantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read ↗

Human Immune Responses to Adeno-Associated Virus (AAV) VectorsSemantic proximity Read ↗

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerationsSemantic proximity Read ↗

Understanding and Tackling Immune Responses to Adeno-Associated Viral VectorsSemantic proximity Read ↗

Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After TrialSemantic proximity Read ↗

Challenges in Humoral Immune Response to Adeno-Associated Viruses DeterminationSemantic proximity Read ↗

Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapySemantic proximity Read ↗

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene TransferSemantic proximity Read ↗

Challenges Posed by Immune Responses to AAV Vectors: Addressing Root CausesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.